Yong Deng1, Xi Zhang1, Michael Simons2. 1. From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (Y.D., X.Z., M.S.) and Department of Cell Biology (X.Z., M.S.), Yale University School of Medicine, New Haven, CT. 2. From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (Y.D., X.Z., M.S.) and Department of Cell Biology (X.Z., M.S.), Yale University School of Medicine, New Haven, CT. michael.simons@yale.edu.
Abstract
OBJECTIVES: Vascular endothelial growth factor receptor 3 (VEGFR3) plays important roles both in lymphangiogenesis and angiogenesis. On stimulation by its ligand VEGF-C, VEGFR3 is able to form both homodimers as well as heterodimers with VEGFR2 and activates several downstream signal pathways, including extracellular signal-regulated kinases (ERK)1/2 and protein kinase B (AKT). Despite certain similarities with VEGFR2, molecular features of VEGFR3 signaling are still largely unknown. APPROACH AND RESULTS: Human dermal lymphatic endothelial cells were used to examine VEGF-C-driven activation of signaling. Compared with VEGF-A activation of VEGFR2, VEGF-C-induced VEGFR3 activation led to a more extensive AKT activation, whereas activation of ERK1/2 displayed a distinctly different kinetics. Furthermore, VEGF-C, but not VEGF-A, induced formation of VEGFR3/VEGFR2 complexes. Silencing VEGFR2 or its partner neuropilin 1 specifically abolished VEGF-C-induced AKT but not ERK activation, whereas silencing of neuropilin 2 had little effect on either signaling pathway. Finally, suppression of vascular endothelial phosphotyrosine phosphatase but not other phosphotyrosine phosphatases enhanced VEGF-C-induced activation of both ERK and AKT pathways. Functionally, both ERK and AKT pathways are important for lymphatic endothelial cells migration. CONCLUSIONS: VEGF-C activates AKT signaling via formation of VEGFR3/VEGFR2 complex, whereas ERK is activated by VEGFR3 homodimer. Neuropilin 1 and vascular endothelial phosphotyrosine phosphatase are involved in regulation of VEGFR3 signaling.
OBJECTIVES:Vascular endothelial growth factor receptor 3 (VEGFR3) plays important roles both in lymphangiogenesis and angiogenesis. On stimulation by its ligand VEGF-C, VEGFR3 is able to form both homodimers as well as heterodimers with VEGFR2 and activates several downstream signal pathways, including extracellular signal-regulated kinases (ERK)1/2 and protein kinase B (AKT). Despite certain similarities with VEGFR2, molecular features of VEGFR3 signaling are still largely unknown. APPROACH AND RESULTS:Human dermal lymphatic endothelial cells were used to examine VEGF-C-driven activation of signaling. Compared with VEGF-A activation of VEGFR2, VEGF-C-induced VEGFR3 activation led to a more extensive AKT activation, whereas activation of ERK1/2 displayed a distinctly different kinetics. Furthermore, VEGF-C, but not VEGF-A, induced formation of VEGFR3/VEGFR2 complexes. Silencing VEGFR2 or its partner neuropilin 1 specifically abolished VEGF-C-induced AKT but not ERK activation, whereas silencing of neuropilin 2 had little effect on either signaling pathway. Finally, suppression of vascular endothelial phosphotyrosine phosphatase but not other phosphotyrosine phosphatases enhanced VEGF-C-induced activation of both ERK and AKT pathways. Functionally, both ERK and AKT pathways are important for lymphatic endothelial cells migration. CONCLUSIONS:VEGF-C activates AKT signaling via formation of VEGFR3/VEGFR2 complex, whereas ERK is activated by VEGFR3 homodimer. Neuropilin 1 and vascular endothelial phosphotyrosine phosphatase are involved in regulation of VEGFR3 signaling.
Authors: Anthony A Lanahan; Diana Lech; Alexandre Dubrac; Jiasheng Zhang; Zhen W Zhuang; Anne Eichmann; Michael Simons Journal: Circulation Date: 2014-06-30 Impact factor: 29.690
Authors: T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo Journal: EMBO J Date: 2001-09-03 Impact factor: 11.598
Authors: Ingrid Nilsson; Fuad Bahram; Xiujuan Li; Laura Gualandi; Sina Koch; Malin Jarvius; Ola Söderberg; Andrey Anisimov; Ivana Kholová; Bronislaw Pytowski; Megan Baldwin; Seppo Ylä-Herttuala; Kari Alitalo; Johan Kreuger; Lena Claesson-Welsh Journal: EMBO J Date: 2010-03-11 Impact factor: 11.598
Authors: Sofie Mellberg; Anna Dimberg; Fuad Bahram; Makoto Hayashi; Emma Rennel; Adam Ameur; Jakub Orzechowski Westholm; Erik Larsson; Per Lindahl; Michael J Cross; Lena Claesson-Welsh Journal: FASEB J Date: 2009-01-09 Impact factor: 5.191
Authors: Yunling Xu; Li Yuan; Judy Mak; Luc Pardanaud; Maresa Caunt; Ian Kasman; Bruno Larrivée; Raquel Del Toro; Steven Suchting; Alexander Medvinsky; Jillian Silva; Jian Yang; Jean-Léon Thomas; Alexander W Koch; Kari Alitalo; Anne Eichmann; Anil Bagri Journal: J Cell Biol Date: 2010-01-11 Impact factor: 10.539
Authors: Jerome W Breslin; Ying Yang; Joshua P Scallan; Richard S Sweat; Shaquria P Adderley; Walter L Murfee Journal: Compr Physiol Date: 2018-12-13 Impact factor: 9.090
Authors: Jesse Gore; Imade E Imasuen-Williams; Abass M Conteh; Kelly E Craven; Monica Cheng; Murray Korc Journal: Cancer Lett Date: 2016-06-03 Impact factor: 8.679
Authors: Kelly L Betterman; Drew L Sutton; Genevieve A Secker; Jan Kazenwadel; Anna Oszmiana; Lillian Lim; Naoyuki Miura; Lydia Sorokin; Benjamin M Hogan; Mark L Kahn; Helen McNeill; Natasha L Harvey Journal: J Clin Invest Date: 2020-06-01 Impact factor: 14.808